Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stem cell company Neuralstem has exclusively licensed the spinal multisegmental cell and drug delivery system invented by Martin Marsala at the University of California, San Diego, for use in spinal cord trials.
Subscribe to our email newsletter
The exclusive, worldwide license to Neuralstem covers all fields of use and includes the right to grant sublicenses. Under the terms of the agreement, University of California, San Diego will be eligible for milestone payments and royalties and Neuralstem will assume the cost of development, manufacture and approval of the product.
Neuralstem reports that its patent-protected technology enables, for the first time, to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.
Richard Garr, CEO of Neuralstem, said: “We believe that Marsala’s injection device will allow for a minimally invasive injection of the cells into the spinal cord, thus significantly reducing the risk of the surgery to any patients receiving cell or drug therapy administered directly into the spinal cord.”